Genmab (GMAB.CO) Stock Analysis & AI Equity Report
Genmab (GMAB.CO) overview
Genmab (GMAB.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, Genmab reported revenue of USD 3,860m and operating profit of USD 1,297m; the year-end share price was 2,027.00 DKK and market capitalisation was DKK 125,980m. Genmab is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Genmab's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-06. Data will be refreshed during report generation.
About Genmab
Genmab A/S is an international biotechnology company focused on discovering, developing and commercializing antibody-based medicines for cancer and other serious diseases. Its portfolio spans approved therapies, proprietary technology platforms and a pipeline of investigational products, including bispecific antibodies, antibody-drug conjugates and immune-modulating antibodies. The company also relies on strategic partnerships to advance development and delivery.
Generate the Genmab report
Genmab is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Genmab and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.